{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:19:00Z","timestamp":1783635540182,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Uniwersytet Medyczny w Bialymstoku","doi-asserted-by":"publisher","award":["B.SUB.25.547"],"award-info":[{"award-number":["B.SUB.25.547"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29422-3","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:36:25Z","timestamp":1764567385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thioredoxin and tetraspanin 30 (CD63) as potential biomarkers for angioinvasion in papillary thyroid cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Angelika","family":"Buczy\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ko\u015bciuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Sidorkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Adamska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Siewko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Dzi\u0119cio\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Szelachowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pop\u0142awska-Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Jacek","family":"Kr\u0119towski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"29422_CR1","unstructured":"Lee, K., Anastasopoulou, C., Chandran, C. & Cassaro, S. Thyroid Cancer. StatPearls (2023)."},{"key":"29422_CR2","unstructured":"Limaiem, F., Rehman, A., Mazzoni, T., Anastasopoulou, C. & Mazzoni, T. Papillary Thyroid Carcinoma. StatPearls."},{"key":"29422_CR3","doi-asserted-by":"crossref","unstructured":"Wang, H et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality,and life expectancy, 1970\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet 390(10100), 1084\u20131150 (2017).","DOI":"10.1016\/S0140-6736(17)31833-0"},{"issue":"1","key":"29422_CR4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10434-004-1165-1","volume":"12","author":"PI Haigh","year":"2005","unstructured":"Haigh, P. I., Urbach, D. R. & Rotstein, L. E. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann. Surg. Oncol. 12(1), 81\u201389 (2005).","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"29422_CR5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/ERC-19-0074","volume":"26","author":"K Bergdorf","year":"2019","unstructured":"Bergdorf, K. et al. Papillary thyroid carcinoma behavior: Clues in the tumor microenvironment. Endocr. Relat. Cancer. 26(6), 601\u2013614 (2019).","journal-title":"Endocr. Relat. Cancer"},{"key":"29422_CR6","doi-asserted-by":"publisher","unstructured":"Buczy\u0144ska, A. et al. Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer. Sci. Rep. 13(1). https:\/\/doi.org\/10.1038\/s41598-023-40898-9 (2023).","DOI":"10.1038\/s41598-023-40898-9"},{"key":"29422_CR7","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAE007","author":"A Buczy\u0144ska","year":"2024","unstructured":"Buczy\u0144ska, A. et al. Enhancing angioinvasion assessment in papillary thyroid cancer via a biomarker panel involving TAC, 8-OHdG and sortilin. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE007 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"47","key":"29422_CR8","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1038\/s41388-022-02499-0","volume":"41","author":"S Hong","year":"2022","unstructured":"Hong, S. et al. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability. Oncogene 41(47), 5121\u20135132 (2022).","journal-title":"Oncogene"},{"key":"29422_CR9","doi-asserted-by":"crossref","first-page":"571421","DOI":"10.3389\/fendo.2020.571421","volume":"11","author":"J Krajewska","year":"2020","unstructured":"Krajewska, J. et al. Early diagnosis of Low-Risk papillary thyroid cancer results rather in overtreatment than a better survival. Front. Endocrinol. (Lausanne). 11, 571421 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"29422_CR10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2013.07.003","volume":"27","author":"C Spencer","year":"2013","unstructured":"Spencer, C. & Fatemi, S. Thyroglobulin antibody (TgAb) methods \u2013 Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 27(5), 701\u2013712 (2013).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"29422_CR11","doi-asserted-by":"publisher","unstructured":"Chiovato, L. et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. 139(5 I). https:\/\/doi.org\/10.7326\/0003-4819-139-5_PART_1-200309020-00010 (2003).","DOI":"10.7326\/0003-4819-139-5_PART_1-200309020-00010"},{"issue":"11","key":"29422_CR12","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1210\/jc.2012-2406","volume":"97","author":"F Latrofa","year":"2012","unstructured":"Latrofa, F. et al. Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies. J. Clin. Endocrinol. Metab. 97(11), 3974\u20133982 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"29422_CR13","unstructured":"Miao, S. et al. 9(3), 653\u2013660 (2020)."},{"issue":"9","key":"29422_CR14","first-page":"2436","volume":"15, Page 2436","author":"A Buczy\u0144ska","year":"2023","unstructured":"Buczy\u0144ska, A. et al. The relationship between oxidative status and radioiodine treatment qualification among papillary thyroid cancer patients. Cancers 2023. 15(9), 2436 (2023).","journal-title":"Cancers 2023"},{"key":"29422_CR15","doi-asserted-by":"crossref","unstructured":"Buczy\u0144ska, A. et al. Oxidative stress and radioiodine treatment of differentiated thyroid cancer. 11(1) (2021).","DOI":"10.1038\/s41598-021-96637-5"},{"issue":"12","key":"29422_CR16","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3390\/cancers15123182","volume":"15","author":"M Ko\u015bciuszko","year":"2023","unstructured":"Ko\u015bciuszko, M., Buczy\u0144ska, A., Kr\u0119towski, A. J. & Pop\u0142awska-Kita, A. Could oxidative stress play a role in the development and clinical management of differentiated thyroid cancer? Cancers (Basel). 15(12), 3182 (2023).","journal-title":"Cancers (Basel)"},{"key":"29422_CR17","doi-asserted-by":"publisher","unstructured":"Buczy\u0144ska, A. et al. The relationship between oxidative status and radioiodine treatment qualification among papillary thyroid cancer patients. Cancers (Basel). 15(9). https:\/\/doi.org\/10.3390\/CANCERS15092436 (2023).","DOI":"10.3390\/CANCERS15092436"},{"issue":"4","key":"29422_CR18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2478\/jtim-2023-0124","volume":"11","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. Exosomes and their derivatives as biomarkers and therapeutic delivery agents for cardiovascular diseases: situations and challenges. J. Transl Int. Med. 11(4), 341\u2013354 (2023).","journal-title":"J. Transl Int. Med."},{"key":"29422_CR19","doi-asserted-by":"publisher","unstructured":"Xie, J. et al. Paracrine orchestration of tumor microenvironment remodeling induced by GLO1 potentiates lymph node metastasis in breast cancer. Adv. Sci. (Weinh). 12(32). https:\/\/doi.org\/10.1002\/ADVS.202500722 (2025).","DOI":"10.1002\/ADVS.202500722"},{"key":"29422_CR20","doi-asserted-by":"publisher","unstructured":"Yuan, Z. et al. Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer. Front. Immunol. 15 https:\/\/doi.org\/10.3389\/FIMMU.2024.1382520 (2024).","DOI":"10.3389\/FIMMU.2024.1382520"},{"issue":"10","key":"29422_CR21","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.3390\/biomedicines10102585","volume":"10","author":"O Delcorte","year":"2022","unstructured":"Delcorte, O., Degosserie, J. & Pierreux, C. E. Role of extracellular vesicles in thyroid physiology and diseases: implications for diagnosis and treatment. Biomedicines 10(10), 2585 (2022).","journal-title":"Biomedicines"},{"key":"29422_CR22","unstructured":"Lincoln, D. T. et al. Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness."},{"issue":"11","key":"29422_CR23","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/ATVBAHA.110.209643","volume":"30","author":"LL Dunn","year":"2010","unstructured":"Dunn, L. L., Buckle, A. M., Cooke, J. P. & Ng, M. K. C. The emerging role of the thioredoxin system in angiogenesis. Arterioscler. Thromb. Vasc Biol. 30(11), 2089\u20132098 (2010).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"2","key":"29422_CR24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000505455","volume":"57","author":"R Hou","year":"2020","unstructured":"Hou, R. et al. Thioredoxin1 inactivation mediates the impairment of Ischemia-Induced angiogenesis and further injury in diabetic myocardium. J. Vasc Res. 57(2), 76\u201385 (2020).","journal-title":"J. Vasc Res."},{"key":"29422_CR25","doi-asserted-by":"publisher","unstructured":"Dey, S., Basu, S. & Ranjan, A. Revisiting the role of CD63 as Pro-Tumorigenic or Anti-Tumorigenic tetraspanin in cancers and its theragnostic implications. Adv. Biol. 7(7). https:\/\/doi.org\/10.1002\/ADBI.202300078 (2023).","DOI":"10.1002\/ADBI.202300078"},{"key":"29422_CR26","doi-asserted-by":"crossref","first-page":"1343894","DOI":"10.3389\/fcell.2024.1343894","volume":"12","author":"S Shao","year":"2024","unstructured":"Shao, S. et al. The role of tetraspanins in digestive system tumor development: Update and emerging evidence. Front. Cell. Dev. Biol. 12, 1343894 (2024).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"26","key":"29422_CR27","doi-asserted-by":"crossref","first-page":"19060","DOI":"10.1074\/jbc.M113.468199","volume":"288","author":"S Tugues","year":"2013","unstructured":"Tugues, S. et al. Tetraspanin CD63 promotes vascular endothelial growth factor receptor 2-\u03b21 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo. J. Biol. Chem. 288(26), 19060\u201319071 (2013).","journal-title":"J. Biol. Chem."},{"issue":"6","key":"29422_CR28","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1210\/clinem\/dgad725","volume":"109","author":"G Li","year":"2024","unstructured":"Li, G. et al. Exosome-mediated delivery of miR-519e-5p promotes malignant tumor phenotype and CD8\u2009+\u2009T-Cell exhaustion in metastatic PTC. J. Clin. Endocrinol. Metab. 109(6), 1601\u20131617 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"29422_CR29","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.3390\/biomedicines10102585","volume":"10, Page 2585","author":"O Delcorte","year":"2022","unstructured":"Delcorte, O., Degosserie, J. & Pierreux, C. E. Role of extracellular vesicles in thyroid physiology and diseases: Implications for diagnosis and treatment. Biomedicines. 10(10), 2585 (2022).","journal-title":"Biomedicines"},{"issue":"1","key":"29422_CR30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41420-025-02411-1","volume":"11","author":"M Jia","year":"2025","unstructured":"Jia, M. et al. Navigating thyroid cancer complexity: The emerging role of EV-derived non-coding RNAs. Cell. Death Discov. 11(1), 142 (2025).","journal-title":"Cell. Death Discov"},{"key":"29422_CR31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","volume":"66","author":"J Lu","year":"2014","unstructured":"Lu, J. & Holmgren, A. The thioredoxin antioxidant system. Free Radic Biol. Med. 66, 75\u201387 (2014).","journal-title":"Free Radic Biol. Med."},{"issue":"7","key":"29422_CR32","first-page":"1763","volume":"10, Page 1763","author":"E Chiaradia","year":"2021","unstructured":"Chiaradia, E. et al. Extracellular vesicles under oxidative stress conditions: biological properties and physiological roles. Cells 2021. 10(7), 1763 (2021).","journal-title":"Cells 2021"},{"key":"29422_CR33","doi-asserted-by":"crossref","first-page":"1261860","DOI":"10.3389\/fendo.2023.1261860","volume":"14","author":"A Buczy\u0144ska","year":"2023","unstructured":"Buczy\u0144ska, A., Ko\u015bciuszko, M., Kr\u0119towski, A. J. & Pop\u0142awska-Kita, A. Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: A literature review. Front. Endocrinol. (Lausanne) 14, 1261860 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"29422_CR34","unstructured":"Jarz\u0105b, B. et al. Zembala-Nozy\u0144ska E, Diagnosis and treatment of thyroid cancer in adult patients - recommendations of polish scientific societies and the national oncological strategy. Endokrynol. Pol. 73(2), 173\u2013300 (2022)."},{"key":"29422_CR35","unstructured":"Nguyen, Q. T. et al. Diagnosis and Treatment of Patients with Thyroid Cancer 30\u201338 (Engage Healthcare Communications, Inc., 2015)."},{"key":"29422_CR36","doi-asserted-by":"crossref","first-page":"1372553","DOI":"10.3389\/fendo.2024.1372553","volume":"15","author":"M Guo","year":"2024","unstructured":"Guo, M., Sun, Y., Wei, Y., Xu, J. & Zhang, C. Advances in targeted therapy and biomarker research in thyroid cancer. Front. Endocrinol. (Lausanne) 15, 1372553 (2024).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"29422_CR37","doi-asserted-by":"crossref","first-page":"9291683","DOI":"10.1155\/2019\/9291683","volume":"2019","author":"W Shang","year":"2019","unstructured":"Shang, W. et al. Increased Thioredoxin-1 expression promotes cancer progression and predicts poor prognosis in patients with gastric cancer. Oxid. Med. Cell. Longev. 2019, 9291683 (2019).","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"11","key":"29422_CR38","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.18632\/oncotarget.3314","volume":"6","author":"J Li","year":"2015","unstructured":"Li, J. et al. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget 6(11), 9551 (2015).","journal-title":"Oncotarget"},{"issue":"9","key":"29422_CR39","first-page":"1078","volume":"13, Page 1078","author":"R Seitz","year":"2024","unstructured":"Seitz, R. et al. Exploring the thioredoxin system as a therapeutic target in cancer: Mechanisms and implications. Antioxid. 2024. 13(9), 1078 (2024).","journal-title":"Antioxid. 2024"},{"key":"29422_CR40","doi-asserted-by":"crossref","first-page":"1080237","DOI":"10.3389\/fonc.2023.1080237","volume":"13","author":"X Liu","year":"2023","unstructured":"Liu, X., Dong, X., Hu, Y. & Fang, Y. Identification of thioredoxin-1 as a biomarker of lung cancer and evaluation of its prognostic value based on bioinformatics analysis. Front. Oncol. 13, 1080237 (2023).","journal-title":"Front. Oncol."},{"issue":"1","key":"29422_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-09033-7","volume":"22","author":"YJ Lee","year":"2022","unstructured":"Lee, Y. J. et al. The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer. BMC Cancer. 22(1), 1\u201314 (2022).","journal-title":"BMC Cancer"},{"key":"29422_CR42","doi-asserted-by":"crossref","unstructured":"Ye, S. et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: A large-scale, multicenter study. Sci. Rep. 9(1), 1\u201312 (2019).","DOI":"10.1038\/s41598-018-38153-7"},{"key":"29422_CR43","doi-asserted-by":"crossref","unstructured":"Zhang, H. et al. Tspan protein family: Focusing on the occurrence, progression, and treatment of cancer. Cell Death Discov. 10(1), 1\u201314 (2024).","DOI":"10.1038\/s41420-024-01961-0"},{"issue":"4","key":"29422_CR44","first-page":"517","volume":"14","author":"Z Chen","year":"2004","unstructured":"Chen, Z. et al. CD82, and CD63 in thyroid cancer. Int. J. Mol. Med. 14(4), 517\u2013527 (2004).","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"29422_CR45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","volume":"15","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh, M. D. A. et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J. Hematol. Oncol. 15(1), 83 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"29422_CR46","doi-asserted-by":"crossref","first-page":"1431581","DOI":"10.3389\/fphar.2024.1431581","volume":"15","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. Exploring exosomes: novel diagnostic and therapeutic frontiers in thyroid cancer. Front. Pharmacol. 15, 1431581 (2024).","journal-title":"Front. Pharmacol."},{"key":"29422_CR47","doi-asserted-by":"publisher","unstructured":"Simantov, R. & Silverstein, R. L. CD36: a critical anti-angiogenic receptor. Front. Biosci. 8(SUPPL.). https:\/\/doi.org\/10.2741\/1168 (2003).","DOI":"10.2741\/1168"},{"issue":"17","key":"29422_CR48","doi-asserted-by":"crossref","first-page":"9319","DOI":"10.3390\/ijms22179319","volume":"22, Page 9319","author":"B La\u00eds Justo","year":"2021","unstructured":"La\u00eds Justo, B., Galvonas Jasiulionis, M., Smetana, K. & Kol\u00e1\u0159, M. Characteristics of TIMP1, CD63, and \u03b21-Integrin and the functional impact of their interaction in cancer. Int. J. Mol. Sci. 2021. 22(17), 9319 (2021).","journal-title":"Int. J. Mol. Sci. 2021"},{"key":"29422_CR49","doi-asserted-by":"crossref","unstructured":"Feng, W. W., Zuppe, H. T. & Kurokawa, M. The role of CD36 in cancer progression and its value as a therapeutic target. ;12(12), 1605. (2023).","DOI":"10.3390\/cells12121605"},{"key":"29422_CR50","doi-asserted-by":"publisher","unstructured":"Rogucki, M. et al. Expression profile and diagnostic significance of MicroRNAs in papillary thyroid cancer. Cancers (Basel) 14(11). https:\/\/doi.org\/10.3390\/CANCERS14112679 (2022).","DOI":"10.3390\/CANCERS14112679"},{"issue":"9","key":"29422_CR51","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/thy.2021.0209","volume":"31","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Predictive value of serum thyroglobulin for structural recurrence following lobectomy for papillary thyroid carcinoma. Thyroid 31(9), 1391\u20131399 (2021).","journal-title":"Thyroid"},{"issue":"4","key":"29422_CR52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ncpendmet0757","volume":"4","author":"CA Spencer","year":"2008","unstructured":"Spencer, C. A. & LoPresti, J. S. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 4(4), 223\u2013233 (2008).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"issue":"1","key":"29422_CR53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cll.2004.01.001","volume":"24","author":"RJ Whitley","year":"2004","unstructured":"Whitley, R. J. & Ain, K. B. Thyroglobulin a specific serum marker for the management of thyroid carcinoma. Clin. Lab. Med. 24(1), 29\u201347 (2004).","journal-title":"Clin. Lab. Med."},{"issue":"3","key":"29422_CR54","first-page":"518","volume":"57","author":"M Prpi\u0107","year":"2018","unstructured":"Prpi\u0107, M., Franceschi, M., Romi\u0107, M., Juki\u0107, T. & Kusi\u0107, Z. Thyroglobulin as a tumor marker in differentiated thyroid cancer\u2014clinical considerations. Acta Clin. Croat. 57(3), 518 (2018).","journal-title":"Acta Clin. Croat"},{"issue":"3","key":"29422_CR55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10408363.2018.1450830","volume":"55","author":"A Algeciras-Schimnich","year":"2018","unstructured":"Algeciras-Schimnich, A. Thyroglobulin measurement in the management of patients with differentiated thyroid cancer. Crit. Rev. Clin. Lab. Sci. 55(3), 205\u2013218 (2018).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"5","key":"29422_CR56","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1210\/jc.2010-2762","volume":"96","author":"C Spencer","year":"2011","unstructured":"Spencer, C., Petrovic, I. & Fatemi, S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low\/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96(5), 1283\u20131291 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"29422_CR57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/a-1232-4575","volume":"53","author":"GMC Landenberger","year":"2021","unstructured":"Landenberger, G. M. C., De Souza Salerno, M. L., Golbert, L. & De Souza Meyer, E. L. Thyroglobulin antibodies as a prognostic factor in papillary thyroid carcinoma patients with indeterminate response after initial therapy. Horm. Metab. Res. 53(2), 94\u201399 (2021).","journal-title":"Horm. Metab. Res."},{"issue":"4","key":"29422_CR58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/EJE-16-0845","volume":"176","author":"H Kwon","year":"2017","unstructured":"Kwon, H. et al. A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: A retrospective individual risk factor-matched cohort study. Eur. J. Endocrinol. 176(4), 371\u2013378 (2017).","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"29422_CR59","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1210\/jc.2003-030122","volume":"88","author":"CM Preissner","year":"2003","unstructured":"Preissner, C. M., O\u2019Kane, D. J., Singh, R. J., Morris, J. C. & Grebe, S. K. G. Phantoms in the assay tube: Heterophile antibody interferences in serum thyroglobulin assays. J. Clin. Endocrinol. Metab. 88(7), 3069\u20133074 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"29422_CR60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1464-5491.2003.01084.x","volume":"21","author":"D Aronson","year":"2004","unstructured":"Aronson, D. et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet. Med. 21(1), 39\u201344 (2004).","journal-title":"Diabet. Med."},{"issue":"3","key":"29422_CR61","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s12020-023-03658-3","volume":"84","author":"A Berli\u0144ska","year":"2024","unstructured":"Berli\u0144ska, A. & \u015awi\u0105tkowska-Stodulska, R. Clinical use of thyroglobulin: Not only thyroid cancer. Endocrine 84(3), 786 (2024).","journal-title":"Endocrine"},{"issue":"12","key":"29422_CR62","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1210\/jc.2014-1203","volume":"99","author":"CA Spencer","year":"2014","unstructured":"Spencer, C. A., Petrovic, I., Fatemi, S. & LoPresti, J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by False-Negative and False-Positive serum thyroglobulin autoantibody misclassifications. J. Clin. Endocrinol. Metab. 99(12), 4589 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"29422_CR63","doi-asserted-by":"publisher","unstructured":"Tronci, L. et al. Crosstalk between metabolic alterations and altered redox balance in PTC-Derived cell lines. Metabolites 9(2). https:\/\/doi.org\/10.3390\/METABO9020023 (2019).","DOI":"10.3390\/METABO9020023"},{"key":"29422_CR64","doi-asserted-by":"crossref","first-page":"682269","DOI":"10.3389\/fcell.2021.682269","volume":"9","author":"N Jiang","year":"2021","unstructured":"Jiang, N. et al. Plasma lipidomics profiling reveals biomarkers for papillary thyroid cancer diagnosis. Front. Cell. Dev. Biol. 9, 682269 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"13","key":"29422_CR65","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.3390\/ijms25137129","volume":"25","author":"M Zwara","year":"2024","unstructured":"Zwara, M. et al. The role of lipid metabolism disorders in the development of thyroid cancer. Int. J. Mol. Sci. 25(13), 7129 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"29422_CR66","doi-asserted-by":"publisher","unstructured":"Tsai, M. C. et al. Association between thyroid cancer and cardiovascular disease risk: A nationwide observation study. Sci. Rep. 12(1). https:\/\/doi.org\/10.1038\/s41598-022-22462-z (2022).","DOI":"10.1038\/s41598-022-22462-z"},{"issue":"3","key":"29422_CR67","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1006\/bbrc.1996.0304","volume":"219","author":"T Furuno","year":"1996","unstructured":"Furuno, T., Teshima, R., Kitani, S., Sawada, J. I. & Nakanishi, M. Surface expression of CD63 antigen (AD1 antigen) in P815 mastocytoma cells by transfected IgE receptors. Biochem. Biophys. Res. Commun. 219(3), 740\u2013744 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"29422_CR68","doi-asserted-by":"crossref","first-page":"e0002","DOI":"10.5041\/RMMJ.10229","volume":"7","author":"ZC Hannoush","year":"2016","unstructured":"Hannoush, Z. C. & Weiss, R. E. Thyroid hormone replacement in patients following thyroidectomy for thyroid cancer. Rambam Maimonides Med. J. 7(1), e0002 (2016).","journal-title":"Rambam Maimonides Med. J."},{"issue":"3","key":"29422_CR69","first-page":"194","volume":"26","author":"A Koljevi\u0107 Markovi\u0107","year":"2023","unstructured":"Koljevi\u0107 Markovi\u0107, A. & Risti\u0107-Medi\u0107, D. Evaluation of vitamin D3 levels and dietary management in patients with papillary thyroid cancer. Hell J. Nucl. Med. 26(3), 194\u2013200 (2023).","journal-title":"Hell J. Nucl. Med."},{"issue":"1","key":"29422_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-40898-9","volume":"13","author":"A Buczy\u0144ska","year":"2023","unstructured":"Buczy\u0144ska, A. et al. Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer. Sci. Rep. 13(1), 1\u201310 (2023).","journal-title":"Sci. Rep."},{"key":"29422_CR71","doi-asserted-by":"publisher","unstructured":"Buczy\u0144ska, A. et al. Oxidative stress and radioiodine treatment of differentiated thyroid cancer. Sci. Rep. 11(1). https:\/\/doi.org\/10.1038\/S41598-021-96637-5 (2021).","DOI":"10.1038\/S41598-021-96637-5"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29422-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:06:26Z","timestamp":1767474386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29422-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["29422"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29422-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Bialystok, Poland (APK.002.7.2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Written informed consent has been obtained from the patients to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"63"}}